Artivion (NYSE:AORT) Given New $46.00 Price Target at Stifel Nicolaus

Artivion (NYSE:AORT) had its target price raised by Stifel Nicolaus from $40.00 to $46.00 in a report released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

AORT has been the topic of a number of other research reports. Wall Street Zen raised Artivion from a “hold” rating to a “buy” rating in a research report on Monday, August 25th. LADENBURG THALM/SH SH cut Artivion from a “buy” rating to a “neutral” rating and increased their target price for the stock from $32.00 to $38.80 in a research note on Wednesday, August 13th. Oppenheimer reaffirmed an “outperform” rating on shares of Artivion in a research note on Friday, August 8th. Canaccord Genuity Group upped their price target on shares of Artivion from $41.00 to $50.00 and gave the company a “buy” rating in a report on Monday. Finally, Needham & Company LLC increased their price objective on shares of Artivion from $45.00 to $50.00 and gave the stock a “buy” rating in a research report on Friday, August 22nd. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Artivion has a consensus rating of “Buy” and a consensus target price of $43.13.

Artivion Trading Up 2.4%

AORT opened at $42.03 on Monday. The firm’s fifty day moving average is $39.55 and its two-hundred day moving average is $31.59. The firm has a market cap of $1.98 billion, a PE ratio of -100.06 and a beta of 1.69. Artivion has a twelve month low of $21.97 and a twelve month high of $45.07. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.48 and a current ratio of 4.78.

Artivion (NYSE:AORT) last released its quarterly earnings data on Thursday, August 7th. The company reported $0.24 EPS for the quarter, beating analysts’ consensus estimates of $0.11 by $0.13. The business had revenue of $112.97 million during the quarter, compared to analysts’ expectations of $107.96 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. The company’s quarterly revenue was up 15.3% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Artivion will post 0.37 EPS for the current year.

Insider Buying and Selling at Artivion

In other news, insider John E. Davis sold 10,802 shares of the business’s stock in a transaction on Tuesday, August 12th. The shares were sold at an average price of $43.67, for a total value of $471,723.34. Following the sale, the insider owned 208,778 shares of the company’s stock, valued at $9,117,335.26. The trade was a 4.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Jean F. Holloway sold 10,000 shares of the firm’s stock in a transaction on Monday, August 25th. The shares were sold at an average price of $44.37, for a total transaction of $443,700.00. Following the completion of the transaction, the senior vice president directly owned 172,129 shares of the company’s stock, valued at approximately $7,637,363.73. This trade represents a 5.49% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 74,858 shares of company stock valued at $3,250,129 over the last ninety days. 8.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Artivion

A number of institutional investors have recently added to or reduced their stakes in AORT. Next Century Growth Investors LLC increased its position in Artivion by 107.6% during the first quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company’s stock worth $25,140,000 after buying an additional 530,122 shares during the last quarter. Peregrine Capital Management LLC acquired a new stake in shares of Artivion in the first quarter valued at approximately $7,650,000. Invesco Ltd. boosted its stake in shares of Artivion by 40.8% during the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company’s stock worth $14,960,000 after acquiring an additional 139,370 shares during the period. Thornburg Investment Management Inc. acquired a new position in shares of Artivion during the 1st quarter worth approximately $3,261,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in shares of Artivion during the 1st quarter worth approximately $3,162,000. 86.37% of the stock is currently owned by institutional investors and hedge funds.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.